Alessandra Viel

List of Publications by Citations

148 papers	6,401 citations	43 h-index	75 g-index
150 ext. papers	7,299 ext. citations	6.3 avg, IF	4.27 L-index

#	Paper	IF	Citations
148	High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. *American Journal of Pathology*, **1999**, 154, 1805-13	5.8	359
147	Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. *Nature Genetics*, **2014**, 46, 107-115	36.3	332
146	Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. *Radiology*, **2007**, 242, 698-715	20.5	287
145	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
144	Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. *American Journal of Pathology*, **2001**, 159, 297-304	5.8	253
143	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
142	Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. *Human Mutation*, **2001**, 18, 163-4	4.7	206
141	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
140	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
139	Human MRE11 is inactivated in mismatch repair-deficient cancers. *EMBO Reports*, **2002**, 3, 248-54	6.5	153
138	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
137	Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. *International Journal of Cancer*, **2004**, 109, 680-4	7.5	143
136	A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. *EBioMedicine*, **2017**, 20, 39-49	8.8	112
135	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
134	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
133	Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. *Journal of Clinical Oncology*, **2001**, 19, 3944-50	2.2	91
132	Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. *Oncogene*, **2004**, 23, 2640-7	9.2	88

131	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research* , **2014**, 16, 3419	8.3	82
130	Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. *Digestive and Liver Disease*, **2013**, 45, 606-11	3.3	79
129	Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients. *Carcinogenesis*, **2010**, 31, 2124-6	4.6	79
128	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. *PLoS Genetics*, **2010**, 6, e1001183	6	74
127	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. *PLoS Biology*, **2011**, 9, e1001199	9.7	73
126	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. *Human Molecular Genetics*, **2015**, 24, 5345-55	5.6	68
125	Hereditary nonpolyposis colorectal cancer: review of clinical, molecular genetics, and counseling aspects. *American Journal of Medical Genetics Part A*, **1996**, 62, 353-64		68
124	Role of MUTYH in human cancer. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2013**, 743-744, 33-43	3.3	66
123	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65
122	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
121	Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. *BMC Cancer*, **2005**, 5, 70	4.8	62
120	Characterization of MSH2 and MLH1 mutations in Italian families with hereditary nonpolyposis colorectal cancer. *Genes Chromosomes and Cancer*, **1997**, 18, 8-18	5	60
119	Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. *Breast Cancer Research and Treatment*, **2012**, 134, 411-8	4.4	58
118	Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas. *British Journal of Cancer*, **1997**, 75, 1105-10	8.7	58
117	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
116	Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. *American Journal of Gastroenterology*, **2005**, 100, 1886-91	0.7	56
115	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
114	Characterization of MLH1 and MSH2 alternative splicing and its relevance to molecular testing of colorectal cancer susceptibility. *Human Genetics*, **1998**, 102, 15-20	6.3	53

113	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Human Mutation*, **2019**, 40, 1557-1578	4.7	52
112	Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. *British Journal of Cancer*, **2004**, 90, 882-7	8.7	50
111	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
110	Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. *European Journal of Human Genetics*, **2004**, 12, 899-906	5.3	46
109	Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines. *British Journal of Cancer*, **1991**, 63, 51-6	8.7	46
108	Chromosomal localisation of two putative 11p oncosuppressor genes involved in human ovarian tumours. *British Journal of Cancer*, **1992**, 66, 1030-6	8.7	46
107	Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations. *Genes Chromosomes and Cancer*, **2006**, 45, 791-7	5	45
106	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
105	Survival analysis in families affected by hereditary non-polyposis colorectal cancer. *International Journal of Cancer*, **1997**, 71, 373-6	7.5	43
104	MLH1 and MSH2 constitutional mutations in colorectal cancer families not meeting the standard criteria for hereditary nonpolyposis colorectal cancer. *International Journal of Cancer*, **1998**, 75, 835-9	7.5	42
103	Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC. *Clinical Genetics*, **2007**, 71, 130-9	4	42
102	BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy. *International Journal of Cancer*, **1999**, 83, 5-9	7.5	38
101	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
100	Molecular mechanisms possibly affecting WT1 function in human ovarian tumors. *International Journal of Cancer*, **1994**, 57, 515-21	7.5	37
99	The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. *Human Mutation*, **2004**, 24, 100-1	4.7	36
98	Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. *Clinical Cancer Research*, **2006**, 12, 3389-93	12.9	35
97	Stability of BAT26 in tumours of hereditary nonpolyposis colorectal cancer patients with MSH2 intragenic deletion. *European Journal of Human Genetics*, **2006**, 14, 63-8	5.3	35
96	Expression of glutathione-S-transferase-pi in human tumours. *European Journal of Cancer*, **1992**, 28A, 1441-6	7.5	35

95	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
94	Different molecular mechanisms underlie genomic deletions in the MLH1 Gene. *Human Mutation*, **2002**, 20, 368-74	4.7	33
93	Ha-ras-1 restriction fragment length polymorphism and susceptibility to colon adenocarcinoma. *British Journal of Cancer*, **1987**, 56, 1-5	8.7	32
92	Integrated analysis of unclassified variants in mismatch repair genes. *Genetics in Medicine*, **2011**, 13, 115-24	8.1	31
91	Assessment of pathogenicity criteria for constitutional missense mutations of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2. *European Journal of Human Genetics*, **1999**, 7, 778-82	5.3	28
90	MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. *European Journal of Human Genetics*, **2014**, 22, 923-9	5.3	27
89	Concomitant mutation and epimutation of the MLH1 gene in a Lynch syndrome family. *Carcinogenesis*, **2015**, 36, 452-8	4.6	26
88	Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy. *Breast Cancer Research and Treatment*, **2013**, 138, 861-8	4.4	26
87	Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers. *Molecular Cancer Therapeutics*, **2009**, 8, 844-54	6.1	26
86	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
85	Loss of MUTYH function in human cells leads to accumulation of oxidative damage and genetic instability. *Oncogene*, **2013**, 32, 4500-8	9.2	25
84	Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features. *European Journal of Human Genetics*, **2006**, 14, 853-9	5.3	25
83	Aetiology of colorectal cancer and relevance of monogenic inheritance. *Gut*, **2004**, 53, 115-22	19.2	25
82	The role of MYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle. *Cancer Letters*, **2008**, 268, 308-13	9.9	23
81	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
80	Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. *Cancer*, **2017**, 123, 210-218	6.4	22
79	Homocysteine accumulation in human ovarian carcinoma ascitic/cystic fluids possibly caused by metabolic alteration of the methionine cycle in ovarian carcinoma cells. *European Journal of Cancer*, **1997**, 33, 1284-90	7.5	22
78	Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer. *International Journal of Cancer*, **1998**, 78, 581-6	7.5	22

77	A mononucleotide markers panel to identify hMLH1/hMSH2 germline mutations. *Disease Markers*, **2007**, 23, 179-87	3.2	22
76	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers. *Breast Cancer Research and Treatment*, **2007**, 103, 29-36	4.4	22
75	Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. *Breast Cancer Research and Treatment*, **2003**, 81, 71-9	4.4	22
74	Mutations of the Ominor Omismatch repair gene MSH6 in typical and atypical hereditary nonpolyposis colorectal cancer. *Familial Cancer*, **2001**, 1, 93-9	3	22
73	Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. *International Journal of Cancer*, **2019**, 145, 390-400	7.5	22
72	Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy. *European Journal of Cancer*, **2015**, 51, 2289-95	7.5	20
71	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
70	Molecular and Pathological Features of Gastric Cancer in Lynch Syndrome and Familial Adenomatous Polyposis. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	20
69	Early-age-at-onset colorectal cancer and microsatellite instability as markers of hereditary nonpolyposis colorectal cancer. *Diseases of the Colon and Rectum*, **2003**, 46, 305-12	3.1	20
68	Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis. *Oncotarget*, **2015**, 6, 42892-3904	5.3	20
67	A genetic model for determining MSH2 and MLH1 carrier probabilities based on family history and tumor microsatellite instability. *Clinical Genetics*, **2006**, 69, 254-62	4	18
66	BRCA1 modulates the expression of hnRNPA2B1 and KHSRP. *Cell Cycle*, **2010**, 9, 4666-73	4.7	17
65	Clinical and biologic heterogeneity of hereditary nonpolyposis colorectal cancer. *International Journal of Cancer*, **2001**, 95, 323-8	7.5	17
64	Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics. *Breast*, **2013**, 22, 1130-5	3.6	16
63	Exploring the link between MORF4L1 and risk of breast cancer. *Breast Cancer Research*, **2011**, 13, R40	8.3	16
62	Somatic mosaicism in a patient with Lynch syndrome. *American Journal of Medical Genetics, Part A*, **2009**, 149A, 212-5	2.5	16
61	Expression of the mdr1 gene in human colorectal carcinomas: relationship with multidrug resistance inferred from analysis of human colorectal carcinoma cell lines. *Cancer Chemotherapy and Pharmacology*, **1992**, 29, 283-9	3.5	16
60	c-myc overexpression is a tumor-specific phenomenon in a subset of human colorectal carcinomas. *Journal of Cancer Research and Clinical Oncology*, **1990**, 116, 288-94	4.9	16

59	An intronic mutation in MLH1 associated with familial colon and breast cancer. *Familial Cancer*, **2011**, 10, 27-35	3	15
58	Four novel MSH2 and MLH1 frameshift mutations and occurrence of a breast cancer phenocopy in hereditary nonpolyposis colorectal cancer. *Human Mutation*, **2001**, 17, 521	4.7	14
57	Small bowel carcinoma in hereditary nonpolyposis colorectal cancer. *American Journal of Gastroenterology*, **1998**, 93, 2219-22	0.7	14
56	Nuclear oncogene amplification or rearrangement is not involved in human colorectal malignancies. *European Journal of Cancer & Clinical Oncology*, **1988**, 24, 1321-8		14
55	Contribution of Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy. *Frontiers in Oncology*, **2018**, 8, 583	5.3	14
54	A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. *Breast*, **2018**, 38, 92-97	3.6	13
53	Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy. *BMC Medical Genetics*, **2016**, 17, 11	2.1	13
52	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). *British Journal of Cancer*, **2009**, 101, 2048-54	8.7	13
51	Proximal colon cancer in patients aged 51-60 years of age should be tested for microsatellites instability. A comment on the Revised Bethesda Guidelines. *International Journal of Colorectal Disease*, **2008**, 23, 801-6	3	13
50	Prevalence of the E1317Q variant of the APC gene in Italian patients with colorectal adenomas. *Genetic Testing and Molecular Biomarkers*, **2002**, 6, 313-7		13
49	Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts **2000**, 27, 424-429		13
48	Sensitivity Pattern of Normal and Ha-Ras Transformed Nih3T3 Fibroblasts to Antineoplastic Drugs. *Tumori*, **1989**, 75, 423-428	1.7	13
47	In K562 leukemia cells treated with doxorubicin and hemin, a decrease in c-myc mRNA expression correlates with loss of self-renewal capability but not with erythroid differentiation. *Leukemia Research*, **1989**, 13, 279-87	2.7	13
46	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
45	MUTYH c.933+3A>C, associated with a severely impaired gene expression, is the first Italian founder mutation in MUTYH-Associated Polyposis. *International Journal of Cancer*, **2013**, 132, 1060-9	7.5	12
44	Evaluation of the replication error phenotype in relation to molecular and clinicopathological features in hereditary and early onset colorectal cancer. *European Journal of Cancer*, **1999**, 35, 289-95	7.5	12
43	Genetic instability in lymphoblastoid cell lines expressing biallelic and monoallelic variants in the human MUTYH gene. *Human Molecular Genetics*, **2014**, 23, 3843-52	5.6	11
42	An American founder mutation in MLH1. *International Journal of Cancer*, **2012**, 130, 2088-95	7.5	11

41	Evidence for a link between TNFRSF11A and risk of breast cancer. *Breast Cancer Research and Treatment*, **2011**, 129, 947-54	4.4	11
40	Identification and classification of hereditary nonpolyposis colorectal cancer (Lynch syndrome): adapting old concepts to recent advancements. Report from the Italian Association for the study of Hereditary Colorectal Tumors Consensus Group. *Diseases of the Colon and Rectum*, **2007**, 50, 2126-34	3.1	11
39	Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. *BMC Cancer*, **2006**, 6, 156	4.8	11
38	Clinical and molecular features of attenuated adenomatous polyposis in northern Italy. *Techniques in Coloproctology*, **2013**, 17, 79-87	2.9	10
37	The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. *Breast Cancer Research and Treatment*, **2011**, 125, 855-60	4.4	10
36	MUC gene abnormalities in sporadic and hereditary mucinous colon cancers with microsatellite instability. *Disease Markers*, **2005**, 21, 121-6	3.2	10
35	Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome. *Neuropathology and Applied Neurobiology*, **2018**, 44, 233-239	5.2	10
34	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
33	Type and frequency of MUTYH variants in Italian patients with suspected MAP: a retrospective multicenter study. *Journal of Human Genetics*, **2017**, 62, 309-315	4.3	9
32	Soft tissue sarcoma and the hereditary non-polyposis colorectal cancer (HNPCC) syndrome: formulation of an hypothesis. *Molecular Biology Reports*, **2012**, 39, 9307-10	2.8	9
31	Genotype-phenotype correlations in individuals with a founder mutation in the MLH1 gene and hereditary non-polyposis colorectal cancer. *Scandinavian Journal of Gastroenterology*, **2007**, 42, 746-53	2.4	9
30	Twelve years of endoscopic surveillance in a family carrying biallelic Y165C MYH defect: report of a case. *Diseases of the Colon and Rectum*, **2006**, 49, 272-5	3.1	8
29	Hereditary nonpolyposis colorectal cancer: an approach to the selection of candidates to genetic testing based on clinical and molecular characteristics. *Public Health Genomics*, **1998**, 1, 229-36	1.9	8
28	Somatic Testing on Gynecological Cancers Improve the Identification of Lynch Syndrome. *International Journal of Gynecological Cancer*, **2017**, 27, 1543-1549	3.5	7
27	Correlation between chromosome 5q deletions and different mechanisms of c-myc overexpression in human colorectal cancer. *British Journal of Cancer*, **1991**, 63, 185-6	8.7	7
26	Toward a better definition of EPCAM deletions in Lynch Syndrome: Report of new variants in Italy and the associated molecular phenotype. *Molecular Genetics & Genomic Medicine*, **2019**, 7, e587	2.3	6
25	Prognostic Relevance of MLH1 and MSH2 Mutations in Hereditary Non-Polyposis Colorectal Cancer Patients. *Tumori*, **2009**, 95, 731-738	1.7	6
24	Polymorphic CAG repeat length within the androgen receptor gene: identification of a subgroup of patients with increased risk of ovarian cancer. *Oncology Reports*, **2002**, 9, 639	3.5	6

23	Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement. *Digestive and Liver Disease*, **2021**, 53, 409-417	3.3	6
22	Factors affecting the treatment of multiple colorectal adenomas. *Surgical Endoscopy and Other Interventional Techniques*, **2013**, 27, 207-13	5.2	4
21	APC I1307K mutations and forkhead box gene (FOXO1A): another piece of an interesting correlation. *International Journal of Biological Markers*, **2012**, 27, 13-9	2.8	4
20	A missense germline mutation in exon 7 of the MSH2 gene in a HNPCC family from center-Italy. *Familial Cancer*, **2007**, 6, 97-102	3	4
19	Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma. *Cancer Biology and Therapy*, **2016**, 17, 1017-1021	4.6	3
18	Disruption of the APC gene by t(5;7) translocation in a Turcot family. *Cancer Genetics*, **2016**, 209, 107-11	2.3	3
17	Mood state profile and coping strategies after BRCA-1/2 genetic test disclosure: a retrospective study in Italy. *Supportive Care in Cancer*, **2011**, 19, 733-5	3.9	3
16	Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers. *BMC Cancer*, **2009**, 9, 360	4.8	3
15	Problems in the identification of hereditary nonpolyposis colorectal cancer in two families with late development of full-blown clinical spectrum. *American Journal of Gastroenterology*, **2000**, 95, 2110-5	0.7	3
14	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
13	Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy. *Tumor Biology*, **2012**, 33, 857-64	2.9	2
12	Reply to Jaskowski et al. *European Journal of Human Genetics*, **2007**, 15, 141-142	5.3	2
11	Frequent Occurrence of Ha-rasl Allelic Deletion in Human Ovarian Adenocarcinomas. *Tumori*, **1991**, 77, 16-20	1.7	2
10	Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. *Endocrine Connections*, **2019**, 8, 1224-1229	3.5	2
9	Correspondence re: Samowitz et al., Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol. Biomark. Prev., 10: 917-923, 2001. *Cancer Epidemiology Biomarkers and Prevention*, **2002**, 11, 499; author reply 499-500	4	2
8	Recommendations for the Molecular Diagnosis of Familial Adenomatous Polyposis. *Tumori*, **1997**, 83, 795-799	1.7	1
7	Microsatellite instability in colorectal cancer: prognostic, predictive or both?. *American Journal of Pathology*, **2002**, 160, 384-5; author reply 385-6	5.8	1
6	Problems in the identification of hereditary nonpolyposis colorectal cancer in two families with late development of full-blown clinical spectrum. *American Journal of Gastroenterology*, **2000**, 95, 2110-2115	0.7	1

5	Filling the gap: A thorough investigation for the genetic diagnosis of unsolved polyposis patients with monoallelic MUTYH pathogenic variants. *Molecular Genetics & Genomic Medicine*, **2021**, e1831	2.3	1
4	Lynch syndrome and Muir-Torre phenotype associated with a recurrent variant in the 3'UTR of the MSH6 gene. *Cancer Genetics*, **2021**, 254-255, 1-10	2.3	1
3	Massive juvenile polyposis of the stomach in a family with SMAD4 gene mutation. *Familial Cancer*, **2019**, 18, 165-172	3	1
2	Deep sequencing of the X chromosome reveals the proliferation history of colorectal adenomas. *Genome Biology*, **2014**, 15, 437	18.3	0
1	Activation by Point Mutation of Ki-ras Gene Occurring in Transfected Human Normal dna. *Tumori*, **1988**, 74, 499-506	1.7	